久久久一本精品,亚洲美女一区二区三区,五月天婷亚洲天综合网鲁鲁鲁

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Company News

Company News Exhibitions Activities

All news 2025 2024 2023 2022 2021 2018

Gan & Lee Pharmaceuticals' Overseas Clinical Research on Three Insulin Products was Published in Journal Diabetes, Obesity and Metabolism
Gan & Lee 2023-10-16
EASD 2023丨Diabetes Treatment - Basalin?? Adds Two New Overseas Phase III Clinical Evidence
Gan & Lee 2023-10-11
The Scientific Evaluation from EMA on the Marketing Authorisation Application of Gan & Lee Insulin Aspart biosimilar starts upon the Positive Validation Letter
Gan & Lee 2023-10-09
The Scientific Evaluation from EMA on Marketing Authorisation Application of Gan & Lee Insulin Lispro biosimilar Starts upon the Positive Validation Letter
Gan & Lee 2023-10-09
Highlights Preview! Clinical Data from Two Overseas Phase III Studies of Gan & Lee Pharmaceuticals’ Insulin Glargine Selected for EASD 2023
Gan & Lee 2023-09-26
Gan & Lee Pharmaceuticals' Once-Weekly Insulin GZR4 Completes First Dosing in Phase II Clinical Trial
Gan & Lee 2023-09-14

< 1 2 3 4 >

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Subscribe